New cream tested to halt scarring hair loss
NCT ID NCT07487948
Summary
This study is testing a topical cream called delgocitinib for adults with two types of scarring hair loss: central centrifugal cicatricial alopecia (CCCA) and lichen planopilaris (LPP). About 30 participants will apply the cream twice daily for 48 weeks to see if it's safe and if it reduces scalp inflammation and scarring. The main goal is to see if the cream changes certain markers in the scalp and if it helps control the disease and improve hair growth.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CENTRAL CENTRIFUGAL CICATRICIAL ALOPECIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Icahn School of Medicine at Mount Sinai
New York, New York, 10029, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.